These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9469628)

  • 21. Discrepant sensitivity of thromboplastin reagents to clotting factor levels explored by the prothrombin time in patients on stable oral anticoagulant treatment: impact on the international normalized ratio system.
    Testa S; Morstabilini G; Fattorini A; Galli L; Denti N; D'Angelo A
    Haematologica; 2002 Dec; 87(12):1265-73. PubMed ID: 12495900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. INR comparison between the CoaguChek S and a standard laboratory method among patients with self-management of oral anticoagulation.
    Hentrich DP; Fritschi J; Müller PR; Wuillemin WA
    Thromb Res; 2007; 119(4):489-95. PubMed ID: 16765423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Problems of long-term therapy with anticoagulants].
    Lechner K; Gaiger A; Fritz A; Kyrle P; Eichinger S; Pabinger I
    Acta Med Austriaca; 1992; 19(1):21-4. PubMed ID: 1585783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Point-of-care monitoring of oral anticoagulation therapy in children. Comparison of the CoaguChek XS system with venous INR and venous INR using an International Reference Thromboplastin preparation (rTF/95).
    Greenway A; Ignjatovic V; Summerhayes R; Newall F; Burgess J; DeRosa L; Monagle P
    Thromb Haemost; 2009 Jul; 102(1):159-65. PubMed ID: 19572081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. International sensitivity index calibration of the near-patient testing prothrombin time monitor, ProTime.
    Tripodi A; Chantarangkul V; Bressi C; Mannucci PM
    Am J Clin Pathol; 2003 Feb; 119(2):241-5. PubMed ID: 12579994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical and laboratory evaluation of patients treated with oral anticoagulation].
    Lourenço DM; Lopes LH; Vignal CV; Morelli VM
    Arq Bras Cardiol; 1997 May; 68(5):353-6. PubMed ID: 9497524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interference of lupus anticoagulants in prothrombin time assays: implications for selection of adequate methods to optimize the management of thrombosis in the antiphospholipid-antibody syndrome.
    Della Valle P; Crippa L; Garlando AM; Pattarini E; Safa O; Viganò D'Angelo S; D'Angelo A
    Haematologica; 1999 Dec; 84(12):1065-74. PubMed ID: 10586206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The international normalization ratio in the monitoring of oral anticoagulant therapy].
    Sansores-García L; Majluf-Cruz AS; Vargas-Vorácková F; Labardini-Méndez J
    Rev Invest Clin; 1993; 45(5):463-7. PubMed ID: 8134728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between total prothrombin, native prothrombin and the International Normalized Ratio (INR).
    Braun PJ; Szewczyk KM
    Thromb Haemost; 1992 Aug; 68(2):160-4. PubMed ID: 1412161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Suggestions and propositions to resolve some issues for standardization of prothrombin time and activated partial thromboplastin time].
    Kagawa K; Fukutake K
    Rinsho Byori; 1999 May; 47(5):431-7. PubMed ID: 10375964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral anticoagulation: improving the risk-benefit ratio.
    Vanscoy GJ; Coax WC
    J Fam Pract; 1995 Sep; 41(3):261-9. PubMed ID: 7650506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of variables affecting PTs/INRs.
    McGlasson DL
    Clin Lab Sci; 1999; 12(6):353-8. PubMed ID: 10724633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [International normalized ratio (INR) for optimal anticoagulant therapy].
    Uetsuka Y; Katsuki T; Aosaki M; Iwade K; Hashimoto A; Koyanagi H; Saito M; Yaginuma Y; Hosoda S
    Kokyu To Junkan; 1993 Sep; 41(9):885-90. PubMed ID: 8210749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. International Normalized Ratio (INR): an improved way to monitor oral anticoagulant therapy.
    Oertel LB
    Nurse Pract; 1995 Sep; 20(9):15-6, 21-2. PubMed ID: 7501312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Audit of community-based anticoagulant monitoring in patients with thromboembolic disease: is frequent testing necessary?
    Young L; Ockelford P; Harper P
    Intern Med J; 2004 Nov; 34(11):639-41. PubMed ID: 15546458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved therapeutic safety of oral anticoagulant therapy in Germany: the Saarland model.
    Mörsdorf S; Leipnitz G; Pindur G; Schenk JF; Erdlenbruch W; Krischek B; Wenzel E
    Semin Thromb Hemost; 1999; 25(1):49-55. PubMed ID: 10327221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Role of laboratory monitoring in oral anticoagulant therapy].
    D'Angelo G; Calvano D; Giardini C
    Minerva Med; 1993 Jun; 84(6):313-22. PubMed ID: 8336839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. False incoagulable PT-INR results in oral anticoagulant therapy.
    Redaelli R; Corno AR; Somaini MG; Gechtman C; Caimi TM; Baudo F; Morra E
    Thromb Res; 2008; 122(1):137-9. PubMed ID: 17996923
    [No Abstract]   [Full Text] [Related]  

  • 39. Sample carryover in PT-INR determination is it an issue in Oral Anticoagulant Therapy control?
    Corno AR; Redaelli R; Caimi TM; Mostarda G; Caruso R; Morra E
    Thromb Res; 2011 Mar; 127(3):279-81. PubMed ID: 21129767
    [No Abstract]   [Full Text] [Related]  

  • 40. Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study.
    Clark NP; Witt DM; Delate T; Trapp M; Garcia D; Ageno W; Hylek EM; Crowther MA;
    Pharmacotherapy; 2008 Aug; 28(8):960-7. PubMed ID: 18657012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.